Last reviewed: July 2026.
Emergo by UL is one of the world's largest medical-device regulatory-affairs consultancies and — through its UL Solutions parent — has direct access to bundled device testing and certification. It's a strong fit for sponsors who need a single global RA partner across the US, EU and many other regions, or who want testing and certification wrapped into the same relationship. If you're specifically searching for Emergo by UL alternatives for Latin America medical device registration, bioaccess® is purpose-built for that narrower job: LATAM registration across 10 markets on a single all-inclusive flat annual subscription per country, with the registration held through our own in-country entities and a 90-day (low-risk) / 120-day (Class II/III) timeline guarantee. Other established global RA firms (Qserve Group, NAMSA, and similar consultancies) also serve LATAM as part of a broader global scope.
| Metric | bioaccess® | Emergo by UL |
|---|---|---|
| Service focus | LATAM medical device registration + in-country registration holder / importer of record | Global full-lifecycle regulatory affairs consultancy — many regions, many services |
| Geographic scope | 10 Latin American markets (Colombia, Brazil, Mexico, Argentina, Chile, Peru, Panama, Ecuador, El Salvador, Dominican Republic) | Global multi-region — strong in US FDA, EU MDR/IVDR, UK, Canada, Australia, Japan, China and more |
| Pricing model | Single all-inclusive flat annual subscription per country/family (government submission fees + certified/sworn translations + in-country registered agent + regulatory liaison all included) | Category norm across global RA consultancies: registration fees, government/agency fees, translations, and registered-agent / authorized-representative services are typically quoted as separate line items |
| First device family (low-to-mid risk) | USD 7,500/yr, all-inclusive | Category-level: not publicly listed; usually a project quote plus recurring authorized-representative / holder fees |
| Additional device family (same country) | +USD 3,500/yr (unlimited models/references within a family included) | Category-level: typically re-quoted per SKU family; specifics vary by shop |
| Registration holder / importer of record | bioaccess® holds registrations through our own in-country legal entities across 10 LATAM markets | Emergo by UL operates under a global consultancy model; local registration-holder / authorized-representative services vary by country and are commonly outsourced or partnered |
| Timeline commitment | 90 days (low-risk) / 120 days (Class II/III) end-to-end submission timeline guarantee | Category-level: written end-to-end timeline guarantees are uncommon in the global RA consultancy market |
| Regulatory anchoring | LATAM registrations built on FDA / Health Canada / CE-mark reliance pathways (e.g., COFEPRIS vía abreviada, INVIMA reliance) | Broad regulatory coverage worldwide — including original submissions in the US, EU and elsewhere |
Category-level, widely-known facts about Emergo by UL as a global regulatory-affairs consultancy. Competitor pricing statements describe the general category norm, not a company-specific quote. bioaccess® figures reflect our published LATAM registration operating model.
Only in a narrow slice. Emergo by UL is a large, reputable global regulatory-affairs consultancy serving customers across the US, EU and many other regions with the full regulatory lifecycle. bioaccess® is purpose-built for one job: medical device registration and in-country registration-holder / importer-of-record services across 10 Latin American markets. If you need a single global RA partner across many regions, Emergo by UL is often the better fit. If your near-term milestone is LATAM registration with one flat annual fee per country, bioaccess® is purpose-built for it.
The annual subscription per country and device family includes the government submission fees, certified or sworn translations where the agency requires them, the in-country registered agent, and the regulatory liaison. Additional device families in the same country add +USD 3,500/yr (or +USD 5,500 for Class III/IV in Brazil). Electrical/EMC and RF homologation for wireless devices are handled through the country's telecom authority at vendor cost plus a 20% G&A handling fee.
bioaccess® targets 90 days end-to-end for low-risk devices and 120 days for Class II/III devices under our timeline guarantee. Published agency ranges we work inside: INVIMA (Colombia) 45–90 days; ANMAT (Argentina) 42–62 days under Disposición 7516/2025; COFEPRIS (Mexico) 30–60 working days vía abreviada or 60–120 days standard; ISP (Chile) 30–90 days; ANVISA (Brazil) 60–180 days.
Yes — this is a common pattern. Sponsors regularly use Emergo by UL (or a similar global RA consultancy) for US FDA and EU MDR/IVDR work and pair that with bioaccess® for LATAM registration and in-country registration-holder services. Our documentation is designed to be portable and to reuse the FDA or CE technical file so the LATAM submission slots in cleanly.
Choose Emergo by UL (or another global RA consultancy in its category) when your primary need is US FDA original submissions, EU MDR/IVDR with a notified body, MDSAP, or a single global RA partner spanning many regions beyond LATAM. bioaccess® is the right choice when LATAM registration in one or more of our 10 markets is the near-term milestone and you want one flat annual fee with the local entity accountability included.
LATAM Market Access hub · LATAM registration pricing · LATAM Importer of Record guide
Colombia (INVIMA) · Brazil (ANVISA) · Mexico (COFEPRIS) · Argentina (ANMAT) · Chile (ISP)